• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by AgeX Therapeutics, Inc.

    AgeX Therapeutics Reports Third Quarter 2023 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Reports Second Quarter 2023 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Announces Appeal of NYSE American Determination
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Reports First Quarter 2023 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Reports Third Quarter 2022 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Reports Second Quarter 2022 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Reports First Quarter 2022 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Reports Third Quarter 2021 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics Reports Second Quarter 2021 Financial Results
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
    From AgeX Therapeutics, Inc.
    Via Business Wire
    Tickers AGE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.